Exclusive: Cellares expands deal with Bristol Myers on CAR-T asset, eyes manufacturing expansion - Endpoints News endpts.com Submitted by endpointsnews6292 on October 11, 2023 at 11:00 AM in business No comments 50
Exclusive: Andreessen Horowitz-backed Mana.bio launches for AI-designed lipid nanoparticles - Endpoints News endpts.com Submitted by endpointsnews6292 on October 11, 2023 at 11:00 AM in health No comments 18
Hamas strikes could impact some biopharma operations in Israel - Endpoints News endpts.com Submitted by endpointsnews6292 on October 10, 2023 at 3:37 PM in business No comments 30
FDA rejects Alnylam's Onpattro label expansion after adcomm voted in favor - Endpoints News endpts.com Submitted by endpointsnews6292 on October 10, 2023 at 11:48 AM in news No comments 53
Discounts for weight loss drugs are estimated at more than half, fueling questions about price, PBMs and coverage - Endpoints News endpts.com Submitted by endpointsnews6292 on October 7, 2023 at 6:34 PM in health No comments 7
A treasure trove of new leads on drug targets and biomarkers has been uncovered in a huge proteomics study - Endpoints News endpts.com Submitted by endpointsnews6292 on October 7, 2023 at 10:56 AM in business No comments 5
UniQure halves research, lays off 20% while CSO departs in major revamp - Endpoints News endpts.com Submitted by endpointsnews6292 on October 6, 2023 at 11:41 AM in business No comments 20
Gene therapy maker Orchard Therapeutics sells to Kyowa Kirin for $387M cash as lead program awaits 2024 FDA verdict - Endpoints News endpts.com Submitted by endpointsnews6292 on October 6, 2023 at 9:24 AM in business No comments 5
GLP-1 gene therapy triggers 25% weight loss in obese mice, clinical trials planned for next year - Endpoints News endpts.com Submitted by endpointsnews6292 on October 5, 2023 at 9:30 AM in health No comments 55
Updated: Sanofi's $1.5B pact with Teva in IBD adds fuel to anti-TL1A race against Merck, Roivant and Pfizer - Endpoints News endpts.com Submitted by endpointsnews6292 on October 5, 2023 at 7:49 AM in business No comments 56
Lilly's diabetes and obesity leader to retire in broader leadership shuffle as CSO Dan Skovronsky takes on immunology role - Endpoints News endpts.com Submitted by endpointsnews6292 on October 5, 2023 at 11:26 AM in business No comments 41
Novo Nordisk secures FDA approval of RNAi therapy from $3.3B Dicerna takeover - Endpoints News endpts.com Submitted by endpointsnews6292 on October 3, 2023 at 6:57 PM in business No comments 1
Novo Nordisk, Johnson & Johnson, Amgen and Novartis agree to participate in Medicare negotiations - Endpoints News endpts.com Submitted by endpointsnews6292 on October 3, 2023 at 3:57 PM in business No comments 54
Novartis to seek accelerated approval for oral complement inhibitor in rare kidney disease - Endpoints News endpts.com Submitted by endpointsnews6292 on October 3, 2023 at 3:12 PM in business No comments 53
Providence launches Praia Health to help health systems maintain patient relationships - Endpoints News endpts.com Submitted by endpointsnews6292 on October 3, 2023 at 12:00 PM in business No comments 41
FDA unveils new rare disease pilot program to increase agency-sponsor communications - Endpoints News endpts.com Submitted by endpointsnews6292 on September 30, 2023 at 6:47 PM in business No comments 1
FDA approves major depressive drug after rejecting it multiple times in past two decades - Endpoints News endpts.com Submitted by endpointsnews6292 on September 28, 2023 at 7:33 PM in health No comments 24
Exclusive: Pfizer, Ginkgo sign R&D deal worth up to $331M to develop RNA drugs - Endpoints News endpts.com Submitted by endpointsnews6292 on September 27, 2023 at 10:00 AM in business No comments 35
Omega Therapeutics' epigenomic medicines reduce MYC expression by 55% in early study of cancer patients - Endpoints News endpts.com Submitted by endpointsnews6292 on September 26, 2023 at 11:00 AM in business No comments 49
Novo Nordisk’s latest deal with Valo Health aims to boost its cardiometabolic position - Endpoints News endpts.com Submitted by endpointsnews6292 on September 25, 2023 at 2:20 PM in business No comments 41
For decades, cancer drug developers have focused on inhibition. Now, a GV-backed startup is eyeing activation - Endpoints News endpts.com Submitted by endpointsnews6292 on September 25, 2023 at 3:24 PM in health No comments 59
BridgeBio inks $250M PIPE two months after PhIII heart pill win, hints at more financing - Endpoints News endpts.com Submitted by endpointsnews6292 on September 25, 2023 at 2:48 PM in business No comments 40
FDA advisors unanimously reject Intarcia's embattled type 2 diabetes treatment - Endpoints News endpts.com Submitted by endpointsnews6292 on September 22, 2023 at 3:30 PM in business No comments 20
Travere Therapeutics just misses on confirmatory study for kidney disease drug, stock plummets - Endpoints News endpts.com Submitted by endpointsnews6292 on September 21, 2023 at 3:38 PM in business No comments 42
Taysha stops developing a gene therapy amid debate over FDA's stance on ultra-rare trials - Endpoints News endpts.com Submitted by endpointsnews6292 on September 20, 2023 at 3:07 PM in business No comments 14